Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth

Executive Summary

Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.


Related Content

Perrigo Ends 2017 As It Started: Earnings Results Delayed
Amazon OTCs Likely A Worry For Retailers, A Remedy For Perrigo
Shareholders Challenge Perrigo's Defense Against Mylan Offer Two Years Earlier
Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m
Perrigo Makes Its Rx Generics Business Look Right At Home
Perrigo 'Unlocks Value' But Weak 2017 Outlook Impedes Revelry
Starboard Agreement Tilts Perrigo Toward Rx Generics Sale
Perrigo Out From Under VMS Weight As IVC Lifts Private Label Profile
Omega Marks The Alpha Of Perrigo’s OTC Brand Play
Perrigo’s Global Expectations Counter Slower U.S. OTC Growth


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts